P1-398: Designing the next generation of disease modification trials in people with early Alzheimer's disease: Learnings from recently completed programs in mild-to-moderate populations

2013 ◽  
Vol 9 ◽  
pp. P303-P304
Author(s):  
Steven Romano ◽  
Steven Potkin ◽  
Suna Barlas ◽  
Reisa Sperling ◽  
Amir Kalali ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Next Generation ◽  
Disease Modification ◽  
Early Alzheimer’S Disease

scholarly journals NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGY

2020 ◽  
pp. 1-2
Author(s):  
F.M. Longo ◽  
S.M. Massa
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Biological Diversity ◽  
Task Force ◽  
Next Generation ◽  
Disease Modification ◽  
Task Force Report ◽  
Field Point

A recent EU/US CTAD Task Force Report focused on non-amyloid approaches to Alzheimer’s disease (AD) modification (1). While the broad range of targets and therapies highlighted is in some ways sobering, several themes and advances in the field point to principles and technologies that are encouraging and will likely accelerate progress. These themes include: the view that amyloid and non-amyloid approaches might ultimately be complementary or synergistic; the biological diversity of approaches; emerging -omics strategies that might help guide such options; and finally, the incorporation of aging biology into perspectives of target prioritization and disease modification.

Sign in / Sign up

Export Citation Format

Share Document